Individualized Medicine in Managing Patients with T2DM: Enduring Archive Webcast

Title:

Individualized Medicine in Managing Patients with T2DM: Enduring Archive Webcast
Topic: Diabetology
Relevant Terms: A1C & Glycemic Profiles, Age & Duration Of Diabetes, Body Mass Index, Cardiovascular Disease, Genetic Characteristics, Race & Ethnicity
Primary Audience: Endocrinologists; certified diabetes educators; registered nurses; pharmacists; primary care clinicians; healthcare professionals who are interested in the management of patients with type 2 diabetes mellitus
Launch Date: 12-Sep-11
Credits: 2 AMA PRA Category 1 Credits™
2 ACPE contact hours
2 ANCC contact hours
Expiration Date: 12-Sep-12

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Describe patient-specific factors that contribute to the pathogenesis and influence treatment outcomes in patients with T2DM
  2. Assess how individualized therapy should relate to current treatment guidelines and algorithms in enabling effective T2DM patient management
  3. Manage patients with T2DM based on individualized assessments
  4. Provide appropriate care and counsel for patients and families with T2DM
  5. Utilize the knowledge and skills of all members of a multidisciplinary, patient-centered diabetes treatment team

    Faculty

    Lawrence Blonde, MD, FACP, FACE
    Director, Ochsner Diabetes Clinical Research Unit
    Department of Endocrinology, Diabetes, and Metabolism
    Ochsner Medical Center
    New Orleans, Louisiana     Jaime Davidson, MD
    Clinical Professor of Medicine
    Division of Endocrinology
    University of Texas Southwestern Medical Center
    Dallas, Texas     Robert H. Eckel, MD
    Charles A. Boettcher Endowed Chair in Atherosclerosis
    Professor of Medicine
    Division of Endocrinology, Metabolism and Diabetes, and Cardiology
    Director of the Discovery Translation Program of the NIH-funded CCTSI
    University of Colorado Anschutz Medical Campus
    Aurora, Colorado     Jose C. Florez, MD, PhD
    Assistant Professor of Medicine
    Harvard Medical School
    Center for Human Genetic Research
    Diabetes Unit, Department of Medicine
    Massachusetts General Hospital
    Boston, Massachusetts     Samuel Klein, MD
    William H. Danforth Professor of Medicine and Nutritional Science
    Director, Center for Human Nutrition
    Washington University School of Medicine
    St. Louis, Missouri     Richard E. Pratley, MD
    Medical Director, Florida Hospital Diabetes Institute
    Senior Faculty, Translational Research Institute for Metabolism and Diabetes
    Professor, Sanford-Burnham Medical Research Institute at Lake Nona
    Orlando, Florida
    Program Overview
    Emerging data makes it increasingly clear that patients with T2DM may have a spectrum of causal etiologies and associated features that provide potential for more individualized treatment approaches. The Education Station™ activity will begin with an overview of personalized medicine in T2DM. Participants will have the option of selecting from modules discussing the influence of patient-related factors such as race and ethnicity, genetic characteristics, cardiovascular disease status, A1C level and glycemic profiles, age and duration of T2DM, and body mass index (BMI) status on individualizing therapy. The activity will conclude with remarks from the faculty highlighting key takeaways from each of the 6 modules.


    Agenda
    5 minutes
    Overview
    Lawrence Blonde, MD, FACP, FACE, Chairman
    Richard E. Pratley, MD, Chairman
    1 hour,
    45 minutes
    Race and Ethnicity
    Jaime Davidson, MD
     
    Genetic Characteristics
    Jose C. Florez, MD, PhD
     
    Cardiovascular Disease Status
    Robert H. Eckel, MD
     
    A1C Level and Glycemic Profiles
    Lawrence Blonde, MD, FACP, FACE
     
    Age and Duration of T2DM
    Richard E. Pratley, MD
     
    BMI Status
    Samuel Klein, MD
    10 minutes
    Closing Remarks
    All Faculty

    Physician Continuing Medical Education
    Accreditation Statement
    This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Postgraduate Institute for Medicine and ACCELMED. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
     
    Credit Designation
    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    Pharmacist Continuing Education
    Accreditation Statement
      The Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
     
    Credit Designation
    The Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hours (0.2 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number: 0809-9999-11-102-H01-P)
     
    Live ACPE release date: 6/27/2011
    If you have received credit for UAN 0809-9999-11-075-L01-P, you are not eligible for this activity.
     
    Nursing Continuing Education
    Credit Designation
    This educational activity for 2.0 contact hours is provided by the Postgraduate Institute for Medicine.
     
    Accreditation Statement
    The Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
     
    California Board of Registered Nursing
    Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 2.0 contact hours. 
     
    Estimated time to complete activity: 2.0 hours
     
    The Postgraduate Institute for Medicine
    Email: information@pimed.com
    Website: www.pimed.com
     
    Type of Activity
    Knowledge
     
    Fee Information
    There is no fee for this educational activity.
     
    A statement of credit will be issued immediately upon successful completion of the post-test with a score of 70% or better.
     
    Disclosure of Conflicts of Interest
    The Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
     
    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 
     
    Name of Faculty or Presenter
    Reported Financial Relationship
    Lawrence Blonde, MD, FACP, FACE
     
    Consultant Fees: Amylin Pharmaceuticals, Inc.; AstraZeneca; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Daiichi Sankyo, Inc.; GlaxoSmithKline; Halozyme Therapeutics; Johnson & Johnson; MannKind Corporation; Merck & Co., Inc.; Novo Nordisk A/S; Orexigen® Therapeutics, Inc.; Roche Diagnostics; sanofi-aventis; Santarus, Inc.; VeroScience LLC
    Speakers' Bureaus: AstraZeneca; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Daiichi Sankyo, Inc.; Merck & Co., Inc.; Novo Nordisk A/S; Santarus, Inc.; VeroScience, LLC
    Contracted Research: Boehringer Ingelheim GmbH; Lilly USA, LLC; Johnson & Johnson; Novo Nordisk A/S; Roche Diagnostics; sanofi-aventis
    Investment Interest: Amylin Pharmaceuticals, Inc.; Pfizer Inc.
    Jaime Davidson, MD
     
    Consultant Fees: AstraZeneca; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Daiichi Sankyo, Inc.; Lilly USA, LLC; Merck & Co., Inc.; Novo Nordisk A/S
    Speakers' Bureaus: Bayer Healthcare Pharmaceuticals; Lifescan, Inc.; Lilly USA, LLC; Novartis International AG; Novo Nordisk A/S; Roche Diagnostics; Takeda Pharmaceuticals North America, Inc.
    Robert H. Eckel, MD
     
    Consultant Fees: Amylin Pharmaceuticals, Inc.; Esperion Therapeutics, Inc.; GTC Nutrition; GENFIT; Johnson & Johnson; Lilly USA, LLC; Pfizer Inc.
    Contracted Research: diaDexus, Inc.; GlaxoSmithKline; sanofi-aventis
    Jose C. Florez, MD, PhD
    Consultant Fees: AstraZeneca; Daiichi Sankyo, Inc.
    Samuel Klein, MD
     
    Consultant Fees: Ethicon Endo-Surgery, Inc.; Merck & Co., Inc.; Takeda Pharmaceuticals North America, Inc.
    Speakers' Bureaus: Merck & Co., Inc.
    Contracted Research: EnteroMedics Inc.; Novo Nordisk A/S; Pfizer Inc.
    Ownership Interest: Aspire Pharmaceuticals
    Richard E. Pratley, MD
     
    Consultant Fees: AstraZeneca/Bristol-Myers Squibb Partnership; Eisai Inc.; GlaxoSmithKline; Glenmark Generics, Inc., USA; Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis International AG;  Novo Nordisk A/S; Roche Diagnostics; Takeda Pharmaceuticals North America, Inc.
    Speakers' Bureaus: Merck & Co., Inc.
    Contracted Research: GlaxoSmithKline; Lilly USA, LLC; MannKind Corporation; Merck & Co., Inc.; Novartis International AG; Novo Nordisk A/S; Pfizer Inc.; Roche Diagnostics; sanofi-aventis; Takeda Pharmaceuticals North America, Inc.

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
     
    The following PIM planners and managers, Jan Hixon, RN, BSN, MA, Trace Hutchison, PharmD, Julia Kimball, RN, BSN, Samantha Mattiucci, PharmD, Jan Schultz, RN, MSN, CCMEP, Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
     
    The following ACCELMED planners and managers, Stephanie A. Breslan, MS, hereby states that she or her spouse/life partner have no relationships with commercial interests, and the spouse of Janardhan Sampath, PhD, is an employee of Lilly USA, LLC.
     
    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period September 12, 2011 through September 12, 2012 participants must read the learning objectives and faculty disclosures and study the educational activity. 
     
    PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation following the activity. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.
     
    Media
    Internet
     
    Hardware / Software Requirements
    Flash Player 6.0.79 or later (http://www.adobe.com/go/getflash) (Flash Player 7 or later recommended), and one of the following browsers:
    Windows: Internet Explorer 6, Internet Explorer 7, Firefox 1.x and later, Safari 3, Google Chrome, Opera 9.5
    Macintosh: Firefox 1.x and later, Safari 3
    Linux: Firefox 1.x

     
    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM, ACCELMED, and Lilly USA, LLC do not recommend the use of any agent outside of the labeled indications. 
     
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, ACCELMED, and Lilly USA, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     
    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.